drugset / Trial / NCT03608241

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

NCT03608241

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of multiple dose PF-06651600 on single dose OC PK in healthy female subjects. Subjects will be randomized to 1 of 2 treatment sequences.

Timeline

Start
2018-09-21
Primary completion
2018-11-23
Completion
2018-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritlecitinib Small molecule 200 mg Oral
Subject ethinyl estradiol Small molecule 30 ug Oral
Subject levonogestrel Unknown 150 ug Oral

Indications

No indication recorded.